Table 4.
Model | Total Protein/Cr | Transferrin/Cr | RBP/Cr | NGAL/Cr | KIM-1/Cr | MCP-1/Cr | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Standard β | p | Standard β | p | Standard β | p | Standard β | p | Standard β | p | Standard β | p | |
1 | 0.767 | <0.001 | 0.670 | <0.001 | 0.468 | <0.001 | 0.407 | <0.001 | 0.067 | 0.376 | 0.483 | <0.001 |
2 | 0.766 | <0.001 | 0.673 | <0.001 | 0.492 | <0.001 | 0.446 | <0.001 | 0.082 | 0.305 | 0.508 | <0.001 |
3 | 0.702 | <0.001 | 0.609 | <0.001 | 0.442 | <0.001 | 0.401 | <0.001 | 0.143 | 0.055 | 0.463 | <0.001 |
4 | 0.606 | <0.001 | 0.427 | <0.001 | 0.218 | <0.001 | 0.184 | 0.002 | 0.033 | 0.572 | 0.252 | <0.001 |
Notes: Logarithm-transformed values of ACR, eGFR, and urinary markers were used for analysis. Model 2, adjusted for age, gender, and duration of diabetes. Model 3, adjusted for age, gender, duration of diabetes, FBG, hypertension, hyperlipidemia. Model 4, adjusted for age, gender, duration of diabetes, FBG, hypertension, hyperlipidemia, eGFR. Values of p < 0.05 were considered significant.
Abbreviations: RBP/Cr, retinol-binding protein-to-creatinine ratio; NGAL/Cr, neutrophil gelatinase-associated lipocalin-to-creatinine ratio; KIM-1/Cr, kidney injury molecule 1-to-creatinine ratio; MCP-1/Cr, monocyte chemoattractant protein 1-to-creatinine ratio; Total protein/Cr; total protein-to-creatinine ratio; transferrin/Cr, transferrin-to-creatinine ratio.